Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.

You are here:Home-Chemical Inhibitors & Agonists-Ras-Raf-MAPK-ERK Pathway-Ras-JDQ443
JDQ443

Chemical Structure : JDQ443

CAS No.: 2653994-08-0

JDQ443 (Opnurasib, NVP-JDQ443)

Catalog No.: PC-72897Not For Human Use, Lab Use Only.

JDQ443 (Opnurasib, NVP-JDQ443) is a potent, mutant-selective, covalent KRAS G12C inhibitor.

Packing Price Stock Quantity
1 mg $148 In stock
5 mg $328 In stock
10 mg $528 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Opnurasib (JDQ443, NVP-JDQ443) is a potent, mutant-selective, covalent KRAS G12C inhibitor.
JDQ443 promotes dose-dependent reductions of phosphorylated ERK (pERK) levels and the proliferation of the KRASG12C-mutated cell lines NCI-H358 and NCI-H2122 with IC50 of 18 and 63 nM, respectively. 
JDQ443 binds under the switch II loop with a novel binding mode, exploiting unique interactions with the KRAS G12C protein compared to sotorasib and adagrasib.
JDQ443 potently inhibits KRASG12C cellular signaling and proliferation in a mutant selective manner.
JDQ443 exhibits dose-dependent anti-tumor activity in mice bearing KRAS G12C mutated tumor xenografts comparable to sotorasib and adagrasib.
JDQ443 is orally bioavailable and is well-tolerated.
Combination of JDQ443 with the SHP2 inhibitor TNO155 further increases KRAS G12C target occupancy in vivo, enhanced pre-clinical anti-tumor activity, and delayed the emergence of resistance in xenografts.

Physicochemical Properties

M.Wt 526.03
Formula C29H28ClN7O
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO (5.3 mg/mL)

Chemical Name/SMILES

2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-

References

1. Saskia M. Brachmann, et al. Mol Cancer Ther (2021) 20 (12_Supplement): P124.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: